Core Points - LENZ Therapeutics and Lotus Pharmaceutical have entered into an exclusive licensing and commercialization agreement for LNZ100, aimed at treating presbyopia in South Korea and select Southeast Asian countries [1][2] - The agreement includes up to $125 million in upfront and milestone payments to LENZ, along with tiered, double-digit royalties on future net sales [2] - Lotus will have exclusive rights for the development, manufacturing, registration, and commercialization of LNZ100 in the specified regions [2] Company Overview - LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first aceclidine-based eye drop for presbyopia, a condition affecting approximately 1.8 billion people globally [4] - LNZ100 is a preservative-free, single-use, once-daily eye drop that has undergone a Phase 3 study for registration [4] - The FDA has set a target action date of August 8, 2025, for LNZ100's New Drug Application (NDA) [4] Lotus Pharmaceutical - Founded in 1966, Lotus is an international pharmaceutical company with a strong focus on both novel and generic pharmaceuticals [5] - The company has a robust R&D and manufacturing platform in Asia, certified by major regulatory authorities including the US FDA and EU EMA [5] - Lotus is actively developing over 100 pharmaceutical projects and has a diverse portfolio that includes oncology, complex generics, and biosimilars [6]
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia